Maxim Group Analysts Give Sophiris Bio (SPHS) a $6.00 Price Target
Sophiris Bio (NASDAQ:SPHS) has been assigned a $6.00 price target by research analysts at Maxim Group in a research report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s target price indicates a potential upside of 217.46% from the stock’s current price.
Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Sophiris Bio in a research note on Friday, September 15th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Sophiris Bio has an average rating of “Buy” and an average target price of $6.25.
Shares of Sophiris Bio (NASDAQ SPHS) traded down $0.02 during midday trading on Monday, hitting $1.89. The stock had a trading volume of 154,300 shares, compared to its average volume of 277,600. The company has a current ratio of 13.37, a quick ratio of 13.37 and a debt-to-equity ratio of 0.60. Sophiris Bio has a 1-year low of $1.80 and a 1-year high of $3.24.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.